Tresiba (Insulin Degludec) Patent Expiration, LOE Window & CMS Spending
Tresiba (Insulin Degludec) by Novo Nordisk: Biologic BLA (Purple Book Regime), 0 AB generics, $35.4M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novo Nordisk |
| FDA Application & Pathway | B203314 (BLA) |
| Exclusivity / Cliff Horizon | Biologic BLA (Purple Book Regime) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $35.4M |
| 2024 Medicare Part D Spend | $33.5M |
| 2024 Medicaid Spend | $1.9M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.